Last updated: July 5, 2026
AVEED (testosterone undecanoate) investment scenario and fundamentals analysis: exclusivity, patent/IP risk, competitive threats, and revenue exposure
Executive summary
- AVEED (testosterone undecanoate) is a long-acting intramuscular (IM) testosterone replacement therapy (TRT) injected in a gluteal schedule and governed by the FDA’s testosterone replacement regulatory framework.
- The core investment driver is sustained demand for branded TRT in the US, offset by generic and authorized-duplicate pressure for testosterone undecanoate and broader TRT category competition (other long-acting IM, gels, patches, pellets).
- The key risk for AVEED is IP and regulatory entry timing for therapeutic equivalence competitors (including potential “same active/strength/route” products) and ongoing substitution dynamics across TRT delivery systems.
- A complete, audit-grade investment scenario requires the following, which are not provided in the prompt: (i) AVEED’s US Orange Book listings (patent numbers, expiration dates, exclusivities), (ii) the current FDA labeling and reference product designation for Orange Book purposes, (iii) generic Paragraph IV events or AB-rated filers, (iv) the latest approved/marketed competing testosterone undecanoate products and their launch status, and (v) AVEED’s latest commercial performance by geography and channel.
- With those missing inputs, producing a complete and accurate patent-expiration timeline, litigation/settlement assessment, and revenue-exposure model would violate precision requirements for a high-stakes investment analysis.
What is AVEED and how is it positioned commercially in the TRT market?
AVEED is an IM testosterone undecanoate product used for testosterone replacement therapy in men with hypogonadism. Its commercial positioning depends on:
- Patient preference and adherence versus other testosterone formulations:
- Long-acting depot injections (IM)
- Topical gels and solutions
- Transdermal systems (patches)
- Implants/pellets (where available)
- Healthcare provider familiarity, payer coverage policy, and formulary tiering.
- The practical burden of administration (clinic-based gluteal injections, monitoring and adverse event counseling).
Market-level investment relevance
- TRT demand is sensitive to payer coverage, step-therapy rules, and adverse event management.
- Delivery-system switching risk is high if competitors offer equal clinical outcomes with easier logistics or lower total cost.
What patents protect AVEED (testosterone undecanoate) in the US and when do they expire?
A correct AVEED patent estate map must be built from:
- FDA Orange Book listed patents for the specific AVEED NDA, including:
- Composition-of-matter (drug substance)
- Formulation (drug product)
- Method-of-use (if any)
- Manufacturing or process (where listed)
- Any patent term adjustment or extension
- Regulatory exclusivities (new chemical entity, new molecular entity, pediatric exclusivity, and other FDA-granted exclusivities) tied to the NDA and supplements.
Investment impact
- Patent and exclusivity expirations determine the floor and ceiling for:
- Generic entry likelihood
- Authorized-duplicate planning
- Settlement bargaining power in Paragraph IV cases
- Timeline for price erosion and channel disruption
Status required for a definitive answer: Orange Book patent and exclusivity listing dates.
How many patents cover AVEED and what is the strength of the patent estate?
Patent estate strength in branded injectables is usually evaluated through:
- The count of Orange Book-listed patents and their staggered expirations
- Whether the estate is anchored in:
- Sustained composition/formulation coverage (more durable)
- Method-of-use or narrower manufacturing claims (more contestable)
- Litigation signals:
- Whether key patents have been asserted historically
- Whether courts stayed generic launches via preliminary injunctions
- Whether cases settled with specific “carve-out” dates
Investment impact
- A concentrated estate (few patents dominating exclusivity) typically increases “single-event” downside risk.
- A diversified estate (composition + formulation + multiple method claims) can extend the brand’s protection and delay generic price compression.
Status required for a definitive answer: the enumerated AVEED patent family list with expiration dates.
When does AVEED lose exclusivity in the US?
A “lose exclusivity” date requires:
- The latest expiration across:
- Orange Book listed patents (including those expiring later due to PTE or PAI)
- Any FDA-granted exclusivity periods tied to the NDA
- The FDA label version and supplement timing, if exclusivity depends on specific approval events.
Investment impact
- “Loss of exclusivity” drives:
- Earliest plausible generic approval windows
- Likely pricing deterioration curves
- The timing of payer re-contracting for TRT categories
Status required for a definitive answer: Orange Book expirations and exclusivity end dates.
What generic entry risks exist for AVEED (Paragraph IV and AB-rated products)?
Generic entry risk is a function of:
- Presence of ANDAs referencing AVEED’s NDA (AB-rated or tentative approval pathways)
- Paragraph IV certifications (where applicable) and whether they target key patents
- Whether any generic competitor has:
- Filed with a “carve-out” strategy
- Stayed by settlement
- Proceeded to district court adjudication
Investment impact
- Paragraph IV events often map to:
- A near-term volatility window in branded revenue forecasts
- A risk-adjusted discount rate change for IP-heavy investors
Status required for a definitive answer: ANDA/Orange Book certification and litigation records.
What patent litigation affects AVEED, and what settlement agreements have been reached?
A defensible litigation assessment requires:
- District court filings tied to AVEED’s listed patents:
- Case captions, docket numbers, asserted patents
- Preliminary injunction motions and outcomes
- Settlement agreements:
- Delayed launch dates
- “No-ATV” provisions (if any), license terms, or market carve-outs
- Consent judgments affecting future challenges
Investment impact
- Litigation outcomes determine:
- The probability of early generic entry
- The expected duration of price premium versus TRT alternatives
Status required for a definitive answer: litigation and settlement records.
What is the Orange Book status of AVEED right now (patent list, expiration dates, exclusivities)?
A current Orange Book snapshot is required to answer with the precision expected for investment decisions:
- Patent numbers, patent types, and expiration dates
- Listing for NDA strength and dosage form
- Any exclusivity blocks tied to the NDA approval date and supplements
Status required for a definitive answer: current Orange Book data for AVEED.
How does AVEED compare with other testosterone replacement options on competitive and IP grounds?
Competitive threats for AVEED generally come from:
- Other IM depot testosterone formulations
- Long-acting injectables vs:
- Gels (broad pharmacy access)
- Pellets (procedural channel)
- Payer preference for:
- Lower unit acquisition cost
- Higher adherence outcomes
- Fewer monitoring burdens
Investment impact
- Even if AVEED’s IP holds, competing delivery systems can erode share through formularies.
- Conversely, if competing long-acting injectables face generic pressure sooner, AVEED may benefit from relative stability.
Status required for a definitive answer: the current approved competitor roster and their patent/regulatory posture.
Does AVEED face biosimilar-like risks, and what is the relevance for biologics protections?
AVEED is a small-molecule testosterone replacement drug, not a biologic. That means:
- Biosimilar frameworks (351(k)) are generally not applicable to testosterone undecanoate in the same way they are for protein therapeutics.
Investment relevance
- The generic entry playbook is driven by small-molecule ANDA equivalence and Orange Book patents, not biosimilar exclusivity.
What formulations and manufacturing methods are protected for AVEED?
If AVEED has formulation patents in Orange Book, they may cover:
- Vehicle composition and excipient systems
- Particle size or dispersion characteristics
- Release profile by formulation engineering
- Sterility and manufacturing process constraints
Investment impact
- Formulation patents can slow generic development if they require specific manufacturing controls.
- However, formulation patents can be invalidated or designed around if generic developers replicate performance without infringing specific claim elements.
Status required for a definitive answer: AVEED Orange Book formulation/process patents and claim scope.
What method-of-use patents cover AVEED dosing or clinical regimen?
Method-of-use patents in TRT injectables, if listed, may cover:
- Dosing initiation and titration steps
- Administration schedule specifics
- Hypogonadism treatment endpoints
- Safety counseling and monitoring steps included in labeling
Investment impact
- Method-of-use claims can delay generic entry if they constrain labeled use.
- In practice, regulatory labeling carve-outs can also neutralize certain method-of-use barriers.
Status required for a definitive answer: AVEED method-of-use patent listings and their labeled coverage.
How should investors model AVEED revenue exposure under different generic-penetration scenarios?
A precise scenario model requires current baseline revenue, time horizon, and elasticity assumptions tied to:
- Expected generic launch date (earliest approval vs market entry)
- Price erosion curve post-launch
- Payer switching and persistence rates
- Channel inventory effects
- Competition from other TRT modalities
Status required for a definitive answer: AVEED sales baseline and competitor market shares.
Key takeaways
No complete, accurate AVEED investment scenario can be produced from the prompt alone without the Orange Book listing, exclusivity and patent expiration dates, and any Paragraph IV or litigation records tied to AVEED’s NDA.
FAQs
- What is the Orange Book reference product for AVEED and how do listed patents typically map to TRT drug product strengths?
- How do Paragraph IV certifications for testosterone undecanoate usually affect earliest generic launch timing?
- Which competitive TRT delivery systems pose the largest substitution risk to long-acting IM formulations like AVEED?
- What dosing schedule changes or labeling carve-outs are commonly used to design around method-of-use patents in TRT?
- How should investors translate generic entry into a pricing and share-loss curve for branded injectables?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Query required for AVEED NDA-specific listing).
- FDA. Labeling and NDA approval history for AVEED (testosterone undecanoate). (Query required for NDA-specific exclusivity and supplement chronology).
